secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001558370-24-010964
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo signs joint research agreement for once-monthly obesity therapy DA-1726
-------------------------------------------------------------------------------

- Collaboration with Dong-A ST and ImmunoForge to develop long-acting formulation of GLP1R/GCGR dual agonist DA-1726.
- ImmunoForge's ELP platform can extend drug half-life up to 200x, enabling once-monthly injection.
- DA-1726 currently in Phase 1; financial terms of the agreement not disclosed.
- Goal is to improve patient compliance and ease of administration for obesity treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024010964/0001558370-24-010964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024010964/nrbo-20240806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-010964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer